The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil

Detalhes bibliográficos
Autor(a) principal: Golub, Jonathan E.
Data de Publicação: 2007
Outros Autores: Saraceni, Valeria, Cavalcante, Solange C., Pacheco, Antonio G., Moulton, Lawrence H., King, Bonnie S., Efron, Anne, Moore, Richard D., Chaisson, Richard E., Durovni, Betina
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/57903
Resumo: This work was supported by a Bill and Melinda Gates Foundation grant for the Consortium to Respond Effectively to the AIDS–TB Epidemic (CREATE) and National Institutes of Health grants AI066994 and AI001637.
id CRUZ_4aa39a763e062af19a71dbd8c04d835f
oai_identifier_str oai:www.arca.fiocruz.br:icict/57903
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Golub, Jonathan E.Saraceni, ValeriaCavalcante, Solange C.Pacheco, Antonio G.Moulton, Lawrence H.King, Bonnie S.Efron, AnneMoore, Richard D.Chaisson, Richard E.Durovni, Betina2023-04-20T01:28:00Z2023-04-20T01:28:00Z2007GOLUB, Jonathan E. et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS, v. 21, n. 11, p. 1441-1448, July 11, 2007.0269-9370https://www.arca.fiocruz.br/handle/icict/5790310.1097/QAD.0b013e328216f4411473-5571This work was supported by a Bill and Melinda Gates Foundation grant for the Consortium to Respond Effectively to the AIDS–TB Epidemic (CREATE) and National Institutes of Health grants AI066994 and AI001637.Johns Hopkins University. Center for Tuberculosis Research and Departments of Medicine and International Health. Baltimore, Maryland, USA.Municipal Health Secretariat. Rio de Janeiro, RJ, Brazil.Municipal Health Secretariat. Rio de Janeiro, RJ, Brazil / Fundação Oswaldo Cruz. Instituto Nacional de Pesquisas Evandro Chagas. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.Municipal Health Secretariat. Rio de Janeiro, RJ, Brazil / Fundação Oswaldo Cruz. Instituto Nacional de Pesquisas Evandro Chagas. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.Johns Hopkins University. Center for Tuberculosis Research and Departments of Medicine and International Health. Baltimore, Maryland, USA.Johns Hopkins University. Center for Tuberculosis Research and Departments of Medicine and International Health. Baltimore, Maryland, USA.Johns Hopkins University. Center for Tuberculosis Research and Departments of Medicine and International Health. Baltimore, Maryland, USA.Johns Hopkins University. Center for Tuberculosis Research and Departments of Medicine and International Health. Baltimore, Maryland, USA.Johns Hopkins University. Center for Tuberculosis Research and Departments of Medicine and International Health. Baltimore, Maryland, USA.Municipal Health Secretariat. Rio de Janeiro, RJ, Brazil / Fundação Oswaldo Cruz. Instituto Nacional de Pesquisas Evandro Chagas. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.Background—Tuberculosis is a common complication and leading cause of death in HIV infection. Antiretroviral therapy (ART) lowers the risk of tuberculosis, but may not be sufficient to control HIV-related tuberculosis. Isoniazid preventive therapy (IPT) reduces tuberculosis incidence significantly, but is not widely used. Methods—We analysed tuberculosis incidence in 11 026 HIV-infected patients receiving medical care at 29 public clinics in Rio de Janeiro, Brazil, between 1 September 2003 and 1 September 2005. Data were collected through a retrospective medical record review. We determined rates of tuberculosis in patients who received neither ART nor IPT, only ART, only IPT, or both ART and IPT. Results—The overall tuberculosis incidence was 2.28 cases/100 person-years (PY) [95% confidence interval (CI) 2.06–2.52]. Among patients who received neither ART nor IPT, incidence was 4.01/100 PY. Patients who received ART had an incidence of 1.90/100 PY (95% CI 1.66– 2.17) and those treated with IPT had a rate of 1.27/100 PY (95% CI 0.41–2.95). The incidence among patients who received ART and IPT was 0.80/100 PY (95% CI 0.38–1.47). Multivariate Cox proportional hazards modeling revealed a 76% reduction in tuberculosis risk among patients receiving both ART and IPT (adjusted relative hazard 0.24; P < 0.001) after adjusting for age, previous tuberculosis diagnosis, and CD4 cell counts at baseline. Conclusion—The use of both IPT and ART in HIV-infected patients is associated with significantly reduced tuberculosis incidence. In conjunction with expanded access to ART, the wider use of IPT in patients with HIV will improve tuberculosis control in high burden areas.engLippincott, Williams & WilkinsThe impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazilinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleAntiretroviral therapyBrazilHIVIsoniazidTuberculosisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZORIGINALve_Golub_Jonathan_etal_INI_2007.pdfve_Golub_Jonathan_etal_INI_2007.pdfapplication/pdf392433https://www.arca.fiocruz.br/bitstream/icict/57903/2/ve_Golub_Jonathan_etal_INI_2007.pdf6cc02ada57e2cdc92a8c637e8d7fc09bMD52LICENSElicense.txttext/plain1748https://www.arca.fiocruz.br/bitstream/icict/57903/1/license.txt8a4605be74aa9ea9d79846c1fba20a33MD51icict/579032023-04-19 22:31:44.366oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-04-20T01:31:44Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.en_US.fl_str_mv The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil
title The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil
spellingShingle The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil
Golub, Jonathan E.
Antiretroviral therapy
Brazil
HIV
Isoniazid
Tuberculosis
title_short The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil
title_full The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil
title_fullStr The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil
title_full_unstemmed The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil
title_sort The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil
author Golub, Jonathan E.
author_facet Golub, Jonathan E.
Saraceni, Valeria
Cavalcante, Solange C.
Pacheco, Antonio G.
Moulton, Lawrence H.
King, Bonnie S.
Efron, Anne
Moore, Richard D.
Chaisson, Richard E.
Durovni, Betina
author_role author
author2 Saraceni, Valeria
Cavalcante, Solange C.
Pacheco, Antonio G.
Moulton, Lawrence H.
King, Bonnie S.
Efron, Anne
Moore, Richard D.
Chaisson, Richard E.
Durovni, Betina
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Golub, Jonathan E.
Saraceni, Valeria
Cavalcante, Solange C.
Pacheco, Antonio G.
Moulton, Lawrence H.
King, Bonnie S.
Efron, Anne
Moore, Richard D.
Chaisson, Richard E.
Durovni, Betina
dc.subject.en.en_US.fl_str_mv Antiretroviral therapy
Brazil
HIV
Isoniazid
Tuberculosis
topic Antiretroviral therapy
Brazil
HIV
Isoniazid
Tuberculosis
description This work was supported by a Bill and Melinda Gates Foundation grant for the Consortium to Respond Effectively to the AIDS–TB Epidemic (CREATE) and National Institutes of Health grants AI066994 and AI001637.
publishDate 2007
dc.date.issued.fl_str_mv 2007
dc.date.accessioned.fl_str_mv 2023-04-20T01:28:00Z
dc.date.available.fl_str_mv 2023-04-20T01:28:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv GOLUB, Jonathan E. et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS, v. 21, n. 11, p. 1441-1448, July 11, 2007.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/57903
dc.identifier.issn.en_US.fl_str_mv 0269-9370
dc.identifier.doi.none.fl_str_mv 10.1097/QAD.0b013e328216f441
dc.identifier.eissn.none.fl_str_mv 1473-5571
identifier_str_mv GOLUB, Jonathan E. et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS, v. 21, n. 11, p. 1441-1448, July 11, 2007.
0269-9370
10.1097/QAD.0b013e328216f441
1473-5571
url https://www.arca.fiocruz.br/handle/icict/57903
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Lippincott, Williams & Wilkins
publisher.none.fl_str_mv Lippincott, Williams & Wilkins
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/57903/2/ve_Golub_Jonathan_etal_INI_2007.pdf
https://www.arca.fiocruz.br/bitstream/icict/57903/1/license.txt
bitstream.checksum.fl_str_mv 6cc02ada57e2cdc92a8c637e8d7fc09b
8a4605be74aa9ea9d79846c1fba20a33
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813008950690316288

Registros relacionados